From the Journals
From the Journals
Self-worth training boosts ketamine’s effects in severe depression
The double-blind, randomized clinical trial is the first to assess combining ketamine with a low-cost protective learning program.
From the Journals
‘Disturbing’ lack of follow-up care after psychiatric crises
Patients who had received both primary care and mental health care before an acute event had the highest odds of receiving follow-up.
From the Journals
Teens with diagnosed and undiagnosed ADHD report similar quality of life
Those diagnosed with ADHD in childhood were more than twice as likely to report self-harm.
From the Journals
Dementia signs detected years before diagnosis
Findings of a new study offer hope for interventions to reduce the risk of the dementia developing.
From the Journals
New deep dive into Paxlovid interactions with CVD meds
The review tackles potential drug-drug interactions with the antiviral drug and today’s most commonly prescribed cardiovascular drugs.
From the Journals
Home-based transcranial stimulation succeeds for MDD
Treatment of major depressive disorder at home with real-time supervision improved clinical outcomes that persisted at 6 months.
From the Journals
Poor visual acuity linked to depression, changes in brain structure
Visual impairment was associated with a 19% higher risk for depression.
Latest News
E-health program improves perinatal depression
Patients who used an online intervention showed decreased depression, anxiety, and stress, compared with routine care.
From the Journals
Suicide notes offer ‘unique window’ into motives, risks in the elderly
Most previous studies of late-life suicide have focused on risk factors rather than the themes and meaning underlying individuals’ distress.
From the Journals
63% of long COVID patients are women, study says
The global study also found that about 6% of people with symptomatic infections had long COVID in 2020 and 2021.
From the Journals
Older diabetes drugs linked to dementia risk -- one lower, one higher
“Double-blind and placebo-controlled clinical trials are needed to see whether the drug [TDZ] could help lower dementia risk in people with and...